9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Adjuvant Analgesic Use in the Critically Ill: A Systematic Review and Meta-Analysis

      research-article
      , MD 1 , , BSc 2 , , MD 1, , 2 , , MD 3 , , RN, PhD 4 , , PharmD, FCCM 5 , , PharmD, FCCM 6 , , MD, PhD 7, , 8 , , MD, MSc 3 , , MD, FRCP(c), MSc, FCCM 9 , , PT, PhD 3 , , MD, FCCM 10 , , MD 1 , , MD 11 , , MD 12 , , MLS 13 , , PharmD, MBA, FASHP, FCCM, FNCS 14 , , MD, MSc 3, , 15 ,
      Critical Care Explorations
      Wolters Kluwer Health
      acute pain, analgesics, nonnarcotic, analgesics, opioid, critical illness, meta-analysis, pain management

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Supplemental Digital Content is available in the text.

          Objectives:

          This systematic review and meta-analysis addresses the efficacy and safety of nonopioid adjunctive analgesics for patients in the ICU.

          Data Sources:

          We searched PubMed, Embase, the Cochrane Library, CINAHL Plus, and Web of Science.

          Study Selection:

          Two independent reviewers screened citations. Eligible studies included randomized controlled trials comparing efficacy and safety of an adjuvant-plus-opioid regimen to opioids alone in adult ICU patients.

          Data Extraction:

          We conducted duplicate screening of citations and data abstraction.

          Data Synthesis:

          Of 10,949 initial citations, we identified 34 eligible trials. These trials examined acetaminophen, carbamazepine, clonidine, dexmedetomidine, gabapentin, ketamine, magnesium sulfate, nefopam, nonsteroidal anti-inflammatory drugs (including diclofenac, indomethacin, and ketoprofen), pregabalin, and tramadol as adjunctive analgesics. Use of any adjuvant in addition to an opioid as compared to an opioid alone led to reductions in patient-reported pain scores at 24 hours (standard mean difference, –0.88; 95% CI, –1.29 to –0.47; low certainty) and decreased opioid consumption (in oral morphine equivalents over 24 hr; mean difference, 25.89 mg less; 95% CI, 19.97–31.81 mg less; low certainty). In terms of individual medications, reductions in opioid use were demonstrated with acetaminophen (mean difference, 36.17 mg less; 95% CI, 7.86–64.47 mg less; low certainty), carbamazepine (mean difference, 54.69 mg less; 95% CI, 40.39–to 68.99 mg less; moderate certainty), dexmedetomidine (mean difference, 10.21 mg less; 95% CI, 1.06–19.37 mg less; low certainty), ketamine (mean difference, 36.81 mg less; 95% CI, 27.32–46.30 mg less; low certainty), nefopam (mean difference, 70.89 mg less; 95% CI, 64.46–77.32 mg less; low certainty), nonsteroidal anti-inflammatory drugs (mean difference, 11.07 mg less; 95% CI, 2.7–19.44 mg less; low certainty), and tramadol (mean difference, 22.14 mg less; 95% CI, 6.67–37.61 mg less; moderate certainty).

          Conclusions:

          Clinicians should consider using adjunct agents to limit opioid exposure and improve pain scores in critically ill patients.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine

          Dexmedetomidine is an α2-adrenoceptor agonist with sedative, anxiolytic, sympatholytic, and analgesic-sparing effects, and minimal depression of respiratory function. It is potent and highly selective for α2-receptors with an α2:α1 ratio of 1620:1. Hemodynamic effects, which include transient hypertension, bradycardia, and hypotension, result from the drug’s peripheral vasoconstrictive and sympatholytic properties. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsynaptic α2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique aspect that patients remain easily rousable and cooperative. Dexmedetomidine is rapidly distributed and is mainly hepatically metabolized into inactive metabolites by glucuronidation and hydroxylation. A high inter-individual variability in dexmedetomidine pharmacokinetics has been described, especially in the intensive care unit population. In recent years, multiple pharmacokinetic non-compartmental analyses as well as population pharmacokinetic studies have been performed. Body size, hepatic impairment, and presumably plasma albumin and cardiac output have a significant impact on dexmedetomidine pharmacokinetics. Results regarding other covariates remain inconclusive and warrant further research. Although initially approved for intravenous use for up to 24 h in the adult intensive care unit population only, applications of dexmedetomidine in clinical practice have been widened over the past few years. Procedural sedation with dexmedetomidine was additionally approved by the US Food and Drug Administration in 2003 and dexmedetomidine has appeared useful in multiple off-label applications such as pediatric sedation, intranasal or buccal administration, and use as an adjuvant to local analgesia techniques.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial.

            Delirium is a postoperative complication that occurs frequently in patients older than 65 years, and presages adverse outcomes. We investigated whether prophylactic low-dose dexmedetomidine, a highly selective α2 adrenoceptor agonist, could safely decrease the incidence of delirium in elderly patients after non-cardiac surgery.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions.

              This research determined the safety and efficacy of two small-dose infusions of dexmedetomidine by evaluating sedation, analgesia, cognition, and cardiorespiratory function. Seven healthy young volunteers provided informed consent and participated on three occasions with random assignment to drug or placebo. Heart rate, blood pressure, respiratory rate, ETCO(2), O(2) saturation, and processed electroencephalogram (bispectral analysis) were monitored. Baseline hemodynamic measurements were acquired, and psychometric tests were performed (visual analog scale for sedation; observer's assessment of alertness/sedation scale; digit symbol substitution test; and memory). The pain from a 1-min cold pressor test was quantified with a visual analog scale. After a 10-min initial dose of saline or 6 microg. kg(-1). h(-1) dexmedetomidine, volunteers received 50-min IV infusions of saline, or 0.2 or 0.6 microg. kg(-1). h(-1) dexmedetomidine. Measurements were repeated at the end of infusion and during recovery. The two dexmedetomidine infusions resulted in similar and significant sedation (30%-60%), impairment of memory (approximately 50%), and psychomotor performance (28%-41%). Hemodynamics, oxygen saturation, ETCO(2), and respiratory rate were well preserved throughout the infusion and recovery periods. Pain to the cold pressor test was reduced by 30% during dexmedetomidine infusion. Small-dose dexmedetomidine provided sedation, analgesia, and memory and cognitive impairment. These properties might prove useful in a postoperative or intensive care unit setting. IMPLICATIPNS: The alpha(2) agonist, dexmedetomidine, has sedation and analgesic properties. This study quantified these effects, as well as cardiorespiratory, memory and psychomotor effects, in healthy volunteers. Dexmedetomidine infusions resulted in reversible sedation, mild analgesia, and memory impairment without cardiorespiratory compromise.
                Bookmark

                Author and article information

                Journal
                Crit Care Explor
                Crit Care Explor
                CC9
                Critical Care Explorations
                Wolters Kluwer Health
                2639-8028
                July 2020
                06 July 2020
                : 2
                : 7
                : e0157
                Affiliations
                [1 ]Department of Anesthesia, McMaster University, Hamilton, ON, Canada.
                [2 ]Division of Critical Care, McMaster University, Hamilton, ON, Canada.
                [3 ]Department of Medicine, McMaster University, Hamilton, ON, Canada.
                [4 ]Ingram School of Nursing, McGill University, Montreal, QC, Canada.
                [5 ]Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA.
                [6 ]School of Pharmacy, Northeastern University, Boston, MA.
                [7 ]Department of Anaesthesia and Intensive Care, University of Montpellier Saint Eloi Hospital, Montpellier, France.
                [8 ]PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.
                [9 ]Faculty of Medicine, McGill University, Montreal, QC, Canada.
                [10 ]Division of Anesthesiology, Perioperative Care and Pain Medicine, New York University Langone Health, New York, NY.
                [11 ]Department of Pulmonary and Critical Care, Dokuz Eylul University, Izmir, Turkey.
                [12 ]University of Ottawa, Ottawa, ON, Canada.
                [13 ]Welch Medical Library, Johns Hopkins University, Baltimore, MD.
                [14 ]Johns Hopkins Medical Institutions, Baltimore, MD.
                [15 ]Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
                Author notes
                For information regarding this article, E-mail: rochwerg@ 123456mcmaster.ca
                Article
                00006
                10.1097/CCE.0000000000000157
                7340332
                32696016
                25db4a61-f6c6-4bf8-8235-e4eea17095ec
                Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

                This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

                History
                Categories
                Systematic Review
                Custom metadata
                TRUE
                T

                acute pain,analgesics,nonnarcotic,opioid,critical illness,meta-analysis,pain management

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Cited by21

                Most referenced authors799